As the med tech industry homes in on innovative bionic prosthetic devices, scientists in Germany are developing an artificial hand that uses motion-sensing wires and electrical charges to guide movement.
Covance, recently acquired by testing giant LabCorp, has opened a new, expanded clinical research unit in Texas, pairing space for trials alongside a planned patient-service center operated by its parent company.
Thanks to some recent clinical advances, physicians and scientists--convening in Washington, DC, this week for the Alzheimer's Association International Conference--have some new hope that blasting away some misshapen proteins in the brain called beta amyloids could be a path to finally reversing years of developmental futility.
PRA Health Sciences, looking to find the next generation of clinical researchers, is dialing up its recruitment pitch in hopes of meeting the escalating demand for CRO-run trials around the world.
Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University developed bedside data-acquisition software as part of its infant apnea prevention program. Now, it's spun off the technology into a new startup known as MediCollector.
Roche is resuscitating development for gantenerumab, an Alzheimer's treatment that flamed out in Phase III late last year, as recent clinical results have emboldened the company to launch new studies.
Though it can boast its ownership of the world's bestselling vaccine in Prevnar, Pfizer is not stopping there. On Tuesday, the New York City-based pharma unveiled details of its effort to build out its vaccines business by researching a range of conditions from birth until old age.
Biogen's 6-mg dose of its closely watched Alzheimer's drug aducanumab failed to deliver what the Big Biotech and anxious analysts were hoping to see, falling short of clinical significance on two key measures of efficacy that would have pointed toward a clear path ahead in a pivotal study.
Eli Lilly says that it has evidence to show that its amyloid-busting drug solanezumab has a distinct impact on Alzheimer's disease, pointing to a delayed-start 3.5-year extension study, with a group of patients from the original placebo arm continuing to lag behind patients who started on the drug at the beginning.
A report commissioned by the United Kingdom government has found data to corroborate a widely held belief: R&D collaborations with British universities are expensive. Yet with such institutions performing world-class science--and tax breaks and funding schemes offsetting the upfront costs--Big Pharma is lining up to strike deals. Just ask Pfizer.